Generic Xeljanz XR Availability
Last updated on Apr 10, 2025.
See also: Generic Xeljanz
Xeljanz XR is a brand name of tofacitinib, approved by the FDA in the following formulation(s):
XELJANZ XR (tofacitinib citrate - tablet, extended release;oral)
-
Manufacturer: PFIZER
Approval date: February 23, 2016
Strength(s): EQ 11MG BASE [RLD] [AB] -
Manufacturer: PFIZER
Approval date: December 12, 2019
Strength(s): EQ 22MG BASE [RLD]
Is there a generic version of Xeljanz XR available?
A generic version of Xeljanz XR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Xeljanz XR and have been approved by the FDA:
tofacitinib citrate tablet, extended release;oral
-
Manufacturer: DEXCEL
Approval date: December 16, 2024
Strength(s): EQ 11MG BASE [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xeljanz XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Tofacitinib oral sustained release dosage forms
Patent 10,639,309
Issued: May 5, 2020
Inventor(s): Herbig Scott Max & Krishnaswami Sriram & Kushner & IV Joseph & Lamba Manisha & Stock Thomas C.
Assignee(s): Pfizer Inc.The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
Patent expiration dates:
- March 14, 2034✓
- March 14, 2034
-
Tofacitinib oral sustained release dosage forms
Patent 10639309*PE
Issued: May 5, 2020
Inventor(s): Herbig; Scott Max et al.
Assignee(s): Pfizer Inc. (New York, NY)The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
Patent expiration dates:
- September 14, 2034
- September 14, 2034
-
Tofacitinib oral sustained release dosage forms
Patent 11,253,523
Issued: February 22, 2022
Inventor(s): Herbig Scott Max & Krishnaswami Sriram & Kushner & IV Joseph & Lamba Manisha & Stock Thomas C.
Assignee(s): Pfizer Inc.The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
Patent expiration dates:
- March 14, 2034✓
- March 14, 2034✓
- March 14, 2034✓
- March 14, 2034✓
- March 14, 2034
-
Tofacitinib oral sustained release dosage forms
Patent 11253523*PE
Issued: February 22, 2022
Inventor(s): Herbig; Scott Max et al.
Assignee(s): Pfizer Inc. (New York, NY)The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
Patent expiration dates:
- September 14, 2034
- September 14, 2034
-
Tofacitinib oral sustained release dosage forms
Patent 9,937,181
Issued: April 10, 2018
Inventor(s): Herbig Scott Max & Krishnaswami Sriram & Kushner & IV Joseph & Lamba Manisha & Stock Thomas C
Assignee(s): Pfizer Inc.The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
Patent expiration dates:
- March 14, 2034✓
- March 14, 2034
-
Tofacitinib oral sustained release dosage forms
Patent 9937181*PED
Issued: April 10, 2018
Inventor(s): Herbig; Scott Max et al.
Assignee(s): Pfizer Inc. (New York, NY)The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
Patent expiration dates:
- September 14, 2034✓
- September 14, 2034
-
Pyrrolo[2,3-D]pyrimidine compounds
Patent RE41783
Issued: September 28, 2010
Inventor(s): Blumenkopf; Todd A. et al.
Assignee(s): Pfizer Inc. (Madison, NJ)A compound of the formula ##STR00001## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
Patent expiration dates:
- December 8, 2025✓
- December 8, 2025
-
Pyrrolo[2,3-D]pyrimidine compounds
Patent RE41783*PED
Issued: September 28, 2010
Inventor(s): Blumenkopf; Todd A. et al.
Assignee(s): Pfizer Inc. (Madison, NJ)A compound of the formula ##STR00001## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
Patent expiration dates:
- June 8, 2026✓
- June 8, 2026
More about Xeljanz XR (tofacitinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (17)
- Drug images
- Latest FDA alerts (4)
- Side effects
- Dosage information
- During pregnancy
- Drug class: antirheumatics
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
AB | Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.